Bacterial Toxin Proteases for Mutant Ras Cleavage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments targeting Ras-driven cancers are lacking, as no drugs directly inhibit Ras proteins, which are frequently mutated in human cancers, making them a challenging therapeutic goal.
Innovation Solution
Development of bacterial toxins, specifically the DUF5 proteases from MARTX family toxins, which cleave Ras proteins, including mutant forms, to inhibit cell proliferation by blocking the Ras pathway, using fusion proteins to facilitate cellular delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drugs or therapeutics are used to target Ras proteins, then the treatment approach follows traditional pharmacological methods, but no successful drugs or therapeutics have been developed to directly target Ras proteins or Ras-driven human cancers
Solution Approach 1:
The patent converts the harmful effect of bacterial toxins (which normally kill host cells) into a beneficial therapeutic effect by engineering chimeric proteins that selectively deliver protease activity to cleave and inactivate Ras proteins in cancer cells. The toxin backbone provides efficient cellular delivery, while the attached protease domain provides selective Ras cleavage activity, transforming a harmful bacterial mechanism into a targeted cancer therapy.
Solution Approach 2:
The patent creates composite chimeric proteins by fusing bacterial toxin domains with protease domains. These composite molecules combine the cell-penetrating ability of toxins with the catalytic activity of proteases, enabling selective delivery of Ras-cleaving activity into cancer cells. This composite approach overcomes the limitation of conventional small molecule drugs that cannot effectively target or inactivate Ras proteins.
2Adaptability or versatility
If Ras proteins are targeted for inhibition, then cell proliferation diseases and cancers can be treated, but Ras proteins are frequently mutated and constitute one of the most frequent oncogenic mutations making them challenging to target
Solution Approach 1:
The patent changes the mechanism of Ras inhibition from small molecule binding (which fails with mutations) to proteolytic cleavage. The protease domains in the chimeric proteins recognize and cleave specific peptide bonds in Ras proteins, including mutated forms. This parameter change from pharmacological inhibition to enzymatic degradation overcomes the problem of Ras mutation resistance, as the cleavage mechanism remains effective against various mutant isoforms.
3Ease of operation
If bacterial toxins are used to deliver protease activity, then Ras can be cleaved and cell proliferation blocked, but the toxin must be modified for cellular delivery and therapeutic use
Solution Approach 1:
The patent segments the toxin protein into functional domains and recombines them with protease domains from other sources. The chimeric proteins consist of a toxin backbone (providing delivery function) fused to a protease domain (providing catalytic function). This segmentation allows optimization of each domain's function while creating a unified therapeutic agent that combines efficient cellular delivery with selective Ras cleavage activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The DUF5 proteases effectively inhibit Ras activity, leading to loss of cell proliferation and providing a novel therapeutic approach for Ras-dependent cancers.
Implementation Method 1
it is able to block the Ras pathway, resulting in loss of cell proliferation. Here, we demonstrate, both in vitro and in vivo, that this block occurs because RRSP (DUF5Vv) is an endopeptidase that cleaves Ras within Switch I
Data Source
AI summary
Disclosed are bacterial toxins and uses thereof as specific proteases for Ras sarcoma oncoproteins (Ras proteins). The bacterial toxins may be modified for use as pharmaceutical agents for treating Ras-dependent diseases and disorders including cell proliferation diseases and disorders such as cancer.